Regeneron Expands Ophthalmology Focus Beyond VEGF to Complement and Glaucoma (Q2 2026)

Regeneron’s ophthalmology investment priorities vs. hem/onc (IH/oncology)

1) Beyond VEGF: how Regeneron plans to invest in ophthalmology (complement, glaucoma, and more)

Regeneron’s earnings call messaging indicates it views ophthalmology as a major, multi-program investment priority, not merely a VEGF story. Management explicitly framed an ophthalmology strategy “beyond VEGF,” emphasizing additional disease areas and mechanism/platform expansion, particularly complement and glaucoma. ¹²

Complement-mediated ophthalmology (geographic atrophy)

Management discussed its C5 complement approach in geographic atrophy (GA), stating that its ophthalmology C5 program “remains on track” to report 26-week data from an exploratory cohort in Q4 2026, which will inform a pivotal strategy. ³
Separately, Regeneron also described its broader C5 complement franchise development milestones (e.g., FDA decision in November for cemdisiran/siRNA in generalized myasthenia gravis), reinforcing that complement is a continuing investment area across indications—not only ophthalmology. ⁴

Within ophthalmology, management specifically highlighted that the field needs “safer agents” and “longer-acting agents,” and noted that some patients with GA may also require management of wet AMD, potentially with “simultaneously…multiple injections.” ² They also said they see “devastating consequences” associated with some current complement treatments for GA, which they imply increases the importance of safer complement therapeutics. ²

“EYLEA for glaucoma” positioning (and other eye indications)

Management’s clearest statement on glaucoma was qualitative but direct: Regeneron said it wants to “deliver the sort of successes…with EYLEA for glaucoma,” and similarly for other eye diseases. ²
They also explicitly extended this “EYLEA-for” concept to thyroid eye disease and geographic atrophy and related diseases, tying the strategy to the company’s belief in repeated success across ophthalmic indications. ²

Investment emphasis on ophthalmology success and differentiation

Regeneron said it has a “huge, huge investment belief” in its ophthalmology portfolio, with a goal of bringing “EYLEA”-like differentiated advances “elsewhere.” ² The rationale management gave for continuing investment included: (a) ongoing unmet need and (b) product/clinical needs in GA (safer and longer-acting therapies; addressing comorbidities and injection burden). ²

2) Is ophthalmology a major ongoing focus relative to hem/oncology (IH/onc)?

On the call, Regeneron did not describe ophthalmology as the sole or singular strategic focus. Instead, it portrayed its strategy as broadly diversified across multiple therapeutic areas, while still calling out that it will “continue to focus on I, … all the many areas in I&I.” ² It also stated it “doesn’t take one shot” and instead focuses across immunology/inflammation, cancer, and multiple indications because “many times, the one thing doesn’t work out.” ²⁵

How the company contrasts ophthalmology vs. IH/onc

• Management directly answered an explicit investor question about whether investments in complement/glaucoma ophthalmology imply adding many R&D resources versus whether “hem/onc is the primary focus in I&I.” ¹
• The response: Regeneron affirmed deep commitment to ophthalmology (“huge, huge investment belief”) and described a planned vision of delivering “EYLEA for glaucoma,” “EYLEA for thyroid eye disease,” and analogous successes for GA/related diseases. ²
• At the same time, management emphasized continued focus on cancer and I&I and described their “deepest and broadest…pipeline” as a company-wide strength. ²⁵

Evidence ophthalmology is actively funded and progressing (but hem/onc dominates the near-term “headline” economics)

From the excerpts, there is strong indication that Regeneron’s R&D investment supports a broad pipeline across hem/onc, anticoagulation, and complement-mediated diseases, with R&D expense explicitly tied to supporting the innovative pipeline. ⁶ However, the excerpted financial highlights include:

• Libtayo net product sales growth (and its role as “strategic backbone” for expanding and strengthening oncology) ⁷
• EYLEA HD launch/growth and related commercial execution ⁸

This suggests that, at least in the commercial segment visibility provided in these excerpts, oncology-linked products are emphasized as strategic backbones, while ophthalmology-linked products are also emphasized (EYLEA HD growth and ongoing launches). ⁷⁸

Bottom line

• Beyond VEGF, Regeneron appears to be investing in ophthalmology through complement biology (C5 in GA) and a broader multi-indication ophthalmic vision that explicitly includes glaucoma (“EYLEA for glaucoma”) and thyroid eye disease, alongside GA. ²³
• Relative priority vs. IH/oncology: Based on management’s responses, ophthalmology is presented as a major, ongoing investment belief with multiple programs and continued focus, ² but Regeneron frames its overall strategy as diversified across IH/I&I and oncology rather than ophthalmology replacing hem/onc. ²⁵